Dec 24 2009
Oxford Outcomes, an international health outcomes consultancy, has become a member of SAFE-BioPharma Association, the non-profit association that created and manages the global SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries.
“We joined SAFE-BioPharma in order to reduce the time and cost associated with managing documents. As members we can sign forms and other documents with SAFE-BioPharma digital signatures and virtually eliminate the problems associated with signing, shipping, storing and accessing paper”
The company provides services that support the drug development lifecycle, including patient-reported outcomes research, health economics, epidemiology, infectious disease research, and translation and linguistic validation. It is headquartered in Oxford, U.K., with offices in Canada and the U.S. Its clients include some of the world’s largest biopharmaceutical companies.
“We joined SAFE-BioPharma in order to reduce the time and cost associated with managing documents. As members we can sign forms and other documents with SAFE-BioPharma digital signatures and virtually eliminate the problems associated with signing, shipping, storing and accessing paper,” said Gareth Ellis, Manager of PRO Linguistic Validation services.
SAFE-BioPharma digital signatures provide superior anti-forgery and legal protection to electronic documents than conventional electronic signatures. The SAFE-BioPharma standard also is used extensively for digital identity management and facilitates interoperability across different information systems.
“Becoming a member of SAFE-BioPharma gives Oxford Outcomes the ability to engage more efficiently with its major pharmaceutical clients,” said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association.
Oxford Outcomes, which has around 80 employees worldwide, joined SAFE-BioPharma using the association’s new small-entity pricing.
Duke-NUS sharpens focus on population health and technology-enabled research